|
|
|
|
Barr Pharmaceuticals Inc. Q3 2008 Earnings Call Transcript
Bruce L.Downey - Chairman and CEO William T. McKee - EVP and CFO Christine A. Mundkur - CEO of Barr Laboratories, Inc. Frederick Wilkinson - CEO of Duramed Pharmaceuticals, Inc. Analysts Randall Stanicky - Goldman Sachs Aaron ...
|
|
|
Solvay's pharma sales hold up despite impact of currency
Solvay has posted a 4% rise in sales for the third quarter as its pharmaceuticals division made solid progress on the strong performance of its fenofibrate cardiovascular drugs.Total sales for the Belgian group, which also specialises in...
|
|
|
Financial Report: Abbott 3Q08
3Q Earnings: $1.1 billion (+51%) YTD Revenues: $22.0 billion (+15%) YTD Earnings: $3.3 billion (+39%) Comments: Worldwide pharmaceutical sales were $4.1 billion in the quarter (+17%), driven by growth in Humira, Kaletra, TriCor, and ...
|
|
|
Abbott Reports Strong Sales and Earnings Growth in Third Quarter; Again Raises Full-Year Earnings Outlook
ABBOTT PARK, Ill., Oct.15 /PRNewswire-FirstCall/ -- Abbott today announced financial results for the third quarter ended Sept. 30, 2008. * Diluted earnings per share, excluding specified items, were $0.79, above Abbott's previously...
|
|
|
Abbott Reports Strong Sales and Earnings Growth in Third Quarter; Again Raises Full-Year Earnings Outlook
- Worldwide Sales Increased 17.6 Percent - ABBOTT PARK, Ill., Oct.15 /PRNewswire-FirstCall/ -- Abbott today announced financial results for the third quarter ended Sept. 30, 2008. * Diluted earnings per share, excluding specified...
|
|
|
Abbott Reports Strong Sales and Earnings Growth in Third Quarter; Again Raises Full-Year Earnings Outlook
- Worldwide Sales Increased 17.6 Percent - ABBOTT PARK, Ill., Oct.15 /PRNewswire-FirstCall/ -- Abbott today announced financial results for the third quarter ended Sept. 30, 2008. * Diluted earnings per share, excluding specified...
|
|
|
Abbott net profit zooms by 51%, sales up by 18% in Q3
Abbott has notched up strong growth in sales and earnings during the third quarter ended September 2008 driven by double-digit growth in its leading brands viz., Humira, TriCor, Niaspan and Kaletra.The company's net earnings went up...
|
|
|
Abbott Reports Strong Sales and Earnings Growth in Third Quarter; Again Raises Full-Year Earnings Outlook
ABBOTTPARK, Ill., Oct.15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2008. * Diluted earnings per share, excluding specified items, were $0.79, above Abbott's...
|
|
|
Abbott Reports Strong Sales and Earnings Growth in Third Quarter; Again Raises Full-Year Earnings Outlook
- Worldwide Sales Increased 17.6 Percent - - Adjusted EPS Growth of 17.9 Percent (GAAP EPS up 50.0 Percent) - - Company Raises Earnings-Per-Share Outlook for 2008 - - Double-Digit Sales Growth Reported in Each Major Global Business - -...
|
|
|
Abbott Reports Strong Sales and Earnings Growth in Third Quarter; Again Raises Full-Year Earnings Outlook
ABBOTT PARK, Ill., Oct.15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2008. * Diluted earnings per share, excluding specified items, were $0.79, above Abbott's...
|
|
|
Abbott Reports Strong Sales and Earnings Growth in Third Quarter; Again Raises Full-Year Earnings Outlook
ABBOTT PARK, Ill., Oct.15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2008. * Diluted earnings per share, excluding specified items, were $0.79, above Abbott's...
|
|
|
Abbott Reports Strong Sales and Earnings Growth in Third Quarter; Again Raises Full-Year Earnings Outlook
ABBOTT PARK, Ill., Oct.15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2008. * Diluted earnings per share, excluding specified items, were $0.79, above Abbott's...
|
|
|
Abbott Reports Strong Sales and Earnings Growth in Third Quarter; Again Raises Full-Year Earnings Outlook
ABBOTT PARK, Ill., Oct.15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2008. * Diluted earnings per share, excluding specified items, were $0.79, above Abbott's...
|
|
|
Abbott Reports Strong Sales and Earnings Growth in Third Quarter; Again Raises Full-Year Earnings Outlook
ABBOTT PARK, Ill., Oct.15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2008. * Diluted earnings per share, excluding specified items, were $0.79, above Abbott's...
|
|
|
Abbott Q3 profit rises 51%; Adj. EPS tops consensus; lifts FY08 EPS outlook - Update
(RTTNews) - Healthcare products maker Abbott Laboratories (ABT | Quote | Chart | News | PowerRating) on Wednesday reported a 51% increase in its profit for the third quarter, driven by strong sales of its arthritis drug Humira and its Xience...
|
|
|
Abbott Laboratories Ratings Affirmed Following $5 Billion Share Repurchase; Outlook Stable
NEW YORK Oct.13, 2008--Standard & Poor's Ratings Services said today that it affirmed its ratings on Abbott Laboratories, following the company's announcement of its $5 billion share repurchase program. The outlook remains...
|
